Real-world patterns of growth hormone treatment in Japanese children with short stature associated with small for gestational age, Turner syndrome, Noonan syndrome, achondroplasia, and hypochondroplasia: a retrospective database study
Abstract
In Japan, GH treatment (GHT) is used for short stature associated with small for gestational age (SGA), Noonan syndrome (NS), Turner syndrome (TS), achondroplasia (ACH), and hypochondroplasia (HCH). However, real-world data on these diagnoses and GHT use for these conditions in Japan remain limited. In this retrospective cohort study, we used the JMDC claims database (2005-2021) to extract data of children with SGA-related short stature or diagnosed with short stature diseases, namely NS, TS, ACH, or HCH, particularly in boys aged <17 years and girls aged <15 years. We reported the prevalence, comorbidities, age at diagnosis, time from diagnosis to treatment initiation, persistence to GHT, and proportion of days covered (PDC). We analyzed data from children with SGA-related short stature (n = 786), NS (n = 79), TS (n = 172), ACH (n = 107), and HCH (n = 30); the mean (standard deviation) age at initial diagnosis was 5.2 (3.5), 4.0 (4.0), 6.5 (4.2), 3.0 (4.1), and 4.5 (3.9) years, respectively. The prevalence (per 100,000) was 59.59, 5.45, 9.52, 8.31, and 2.12 for SGA-related short stature, NS, TS, ACH, and HCH, respectively. Mean PDC for SGA-related short stature, NS, TS, ACH, and HCH was 0.918, 0.984, 0.953, 0.941, and 1.000, respectively, demonstrating high persistence to GHT. This study provides insights into the current diagnosis and GHT use among children with short stature in Japan. The findings suggest that most Japanese children continue and adhere well to GHT. However, continued efforts toward early referral and diagnosis remain crucial.
Related
- Perinatal and gestational factors associated with Pavlik harness outcomes in developmental dysplasia of the hip: a retrospective cohort study
- Factors Associated with Predischarge Morbidity and Mortality in Small for Gestational Age Infants: A Single-Center Retrospective Cohort Study
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
- Pre-Existing Mood Disorder is Associated with Higher Odds of Withdrawal of Life-Sustaining Treatment (WOLST) After Severe Stroke: A Retrospective Cohort Study
- Acyclovir and ganciclovir exposure and short-term outcomes in hospitalized children with EBV-associated mononucleosis-like illness: a retrospective cohort study using inverse probability of treatment weighting
BibTeX
@article{mori2026realworld,
title = {{Real-world patterns of growth hormone treatment in Japanese children with short stature associated with small for gestational age, Turner syndrome, Noonan syndrome, achondroplasia, and hypochondroplasia: a retrospective database study}},
author = {Jun Mori and Akie Nakamura and Masanobu Kawai and Satoshi Tsuboi and Yukihito Sato and Takaaki Endo and Sumito Dateki},
journal = {Endocrine Journal},
year = {2026},
month = oct,
doi = {10.1507/endocrj.ej26-0185},
url = {https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0185/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Real-world patterns of growth hormone treatment in Japanese children with short stature associated with small for gestational age, Turner syndrome, Noonan syndrome, achondroplasia, and hypochondroplasia: a retrospective database study
AU - Jun Mori
AU - Akie Nakamura
AU - Masanobu Kawai
AU - Satoshi Tsuboi
AU - Yukihito Sato
AU - Takaaki Endo
AU - Sumito Dateki
PY - 2026
DA - 2026/10/01
JO - Endocrine Journal
DO - 10.1507/endocrj.ej26-0185
UR - https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ26-0185/_article
AB - In Japan, GH treatment (GHT) is used for short stature associated with small for gestational age (SGA), Noonan syndrome (NS), Turner syndrome (TS), achondroplasia (ACH), and hypochondroplasia (HCH). However, real-world data on these diagnoses and GHT use for these conditions in Japan remain limited. In this retrospective cohort study, we used the JMDC claims database (2005-2021) to extract data of children with SGA-related short stature or diagnosed with short stature diseases, namely NS, TS, ACH, or HCH, particularly in boys aged <17 years and girls aged <15 years. We reported the prevalence, comorbidities, age at diagnosis, time from diagnosis to treatment initiation, persistence to GHT, and proportion of days covered (PDC). We analyzed data from children with SGA-related short stature (n = 786), NS (n = 79), TS (n = 172), ACH (n = 107), and HCH (n = 30); the mean (standard deviation) age at initial diagnosis was 5.2 (3.5), 4.0 (4.0), 6.5 (4.2), 3.0 (4.1), and 4.5 (3.9) years, respectively. The prevalence (per 100,000) was 59.59, 5.45, 9.52, 8.31, and 2.12 for SGA-related short stature, NS, TS, ACH, and HCH, respectively. Mean PDC for SGA-related short stature, NS, TS, ACH, and HCH was 0.918, 0.984, 0.953, 0.941, and 1.000, respectively, demonstrating high persistence to GHT. This study provides insights into the current diagnosis and GHT use among children with short stature in Japan. The findings suggest that most Japanese children continue and adhere well to GHT. However, continued efforts toward early referral and diagnosis remain crucial.
SN - 1348-4540
SN - 0918-8959
ER -